Tenax Acquires Rights to Oral Levosimendan, Plans Phase 3 Trial in Type 2 PH
Tenax Therapeutics has acquired developmental and commercial rights for North America to an oral formulation of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax plans to open a Phase 3 safety and efficacy trial of…